Description

CJC-1295 (no DAC) and Ipamorelin are commonly studied together as a complementary research peptide combination due to their distinct yet cooperative activity within the growth hormone signaling pathway. CJC-1295, a modified GHRH analog, is utilized in experimental settings to stimulate endogenous growth hormone release through receptor-mediated cAMP signaling. Ipamorelin, in contrast, is a selective ghrelin receptor agonist that initiates GH secretion via calcium-dependent intracellular pathways.

When evaluated as a combined system, this peptide blend is often used in laboratory research to observe growth hormone pulse dynamics, receptor interaction, and regulatory mechanisms of the hypothalamic–pituitary axis under controlled conditions.

For research use only. Not intended for human consumption.